MCC
APLS

Money Concepts Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Money Concepts Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-175
Closed -$9.05K – 588
2022
Q4 		$9.05K Buy
+175
New +$9.28K ﹤0.01% 2062

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Money Concepts Capital's APLS Position: Q1 2023 in Review

Money Concepts Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 175 shares — an estimated $9.05K sold.

Money Concepts Capital first reported a position in APLS in Q4 2022 and held it in 1 quarter. The position peaked at $9.05K in Q4 2022. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

  • Money Concepts Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 175 Apellis Pharmaceuticals shares in Q1 2023, an estimated $9.05K.
  • Money Concepts Capital first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Money Concepts Capital's Apellis Pharmaceuticals position peaked at $9.05K in Q4 2022.
  • 281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.